mTOR inhibition augments antitumor immune effector response by reprogramming the TP53-mutant, immune-cold HNSCC tumor microenvironment.
Priyatosh Nath, Alok R. Khandelwal, Chun Li, Tara Moore‐Medlin, Srivatsa Surya Vasudevan, Victor Albornoz Alvarez, Omar E. Franco, Jorge Silvio Gutkind, Cherie‐Ann O. Nathan
This study shows that mTOR inhibition with everolimus enhances antitumor immune responses in TP53-mutant HNSCC by altering the tumor microenvironment.
Neoplasia · Aug 8, 2026Peer-reviewedCancer Biology